Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a novel family of BRAF(V600E) inhibitors.

Journal of medicinal chemistry - 14 Jun 2012

Qin Jie, Xie Peng, Ventocilla Christian, Zhou Guoqiang, Vultur Adina, Chen Quan, Liu Qin, Herlyn Meenhard, Winkler Jeffrey, Marmorstein Ronen

Abstract excerpt

The BRAF oncoprotein is mutated in about half of malignant melanomas and other cancers, and a kinase activating single valine to glutamate substitution at residue 600 (BRAF(V600E)) accounts for over 90% of BRAF-mediated cancers. Several BRAF(V600E) inhibitors have been developed, although they harbor some liabilities, thus motivating the development of other BRAF(V600E) inhibitor options. We report here the use...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Screening Assays, Antitumor
Share to Enzyme-Linked Immunosorbent Assay

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Screening Assays

Share to MAP Kinase Signaling System

Share to Melanoma

Share to Molecular Structure

Share to Naphthols

Share to Stereoisomerism

Source

Open in PubMed Open full text

Identifiers

PMID: 22537109
DOI: 10.1021/jm3004416
PMCID: PMC3383862

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a novel family of BRAF(V600E) inhibitors.PMID 22537109Read ↗

Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.Semantic proximity Read ↗

Synthesis, biological evaluation and molecular docking of novel 5-phenyl-1H-pyrazol derivatives as potential BRAF(V600E) inhibitors.Semantic proximity Read ↗

EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.Semantic proximity Read ↗

Discovery and pharmacophore studies of novel pyrazole-based anti-melanoma agents.Semantic proximity Read ↗

BRAF as a therapeutic target: a patent review (2006 - 2012).Semantic proximity Read ↗

Novel and Potent Small Molecules against Melanoma Harboring BRAF Class I/II/III Mutants for Overcoming Drug Resistance.Semantic proximity Read ↗

Pyrimidin-4-bromobenzenesulfonamide/-4-nitrobenzenesulfonamide hybrids as potential BRAFV600E inhibitors: experimental, computational and biological evaluations.Semantic proximity Read ↗

An updated literature on BRAF inhibitors (2018-2023).Semantic proximity Read ↗

Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold.Semantic proximity Read ↗

Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF).Semantic proximity Read ↗

Identification of type II inhibitors targeting BRAF using privileged pharmacophores.Semantic proximity Read ↗

Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.